Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: BONE DENSITY - DRUG EFFECTS , . Treffer: 42

2017

Bone, HG; Wagman, RB; Brandi, ML; Brown, JP; Chapurlat, R; Cummings, SR; Czerwiński, E; Fahrleitner-Pammer, A; Kendler, DL; Lippuner, K; Reginster, JY; Roux, C; Malouf, J; Bradley, MN; Daizadeh, NS; Wang, A; Dakin, P; Pannacciulli, N; Dempster, DW; Papapoulos, S 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Lancet Diabetes Endocrinol. 2017; 5(7):513-523
Web of Science PubMed FullText FullText_MUG

 

Fahrleitner-Pammer, A; Wagner, D; Krisper, P; Amrein, K; Dimai, H Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report.
Osteoporos Int. 2017; 28(3):1149-1152 (- Case Report) [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Schwetz, V; Schnedl, C; Urbanic-Purkart, T; Trummer, C; Dimai, HP; Fahrleitner-Pammer, A; Putz-Bankuti, C; Christopher, KB; Obermayer-Pietsch, B; Pieber, TR; Dobnig, H; Amrein, K Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study.
Osteoporos Int. 2017; 28(12):3347-3354 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Tsourdi, E; Langdahl, B; Cohen-Solal, M; Aubry-Rozier, B; Eriksen, EF; Guañabens, N; Obermayer-Pietsch, B; Ralston, SH; Eastell, R; Zillikens, MC Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS.
Bone. 2017; 105(21-22):11-17
Web of Science PubMed FullText FullText_MUG

 

2016

Fahrleitner-Pammer, A; Burr, D; Dobnig, H; Stepan, JJ; Petto, H; Li, J; Krege, JH; Pavo, I Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.
Bone. 2016; 89(6):16-24 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2015

Muschitz, C; Kocijan, R; Pahr, D; Patsch, JM; Amrein, K; Misof, BM; Kaider, A; Resch, H; Pietschmann, P Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis.
Calcif Tissue Int. 2015; 96(6): 477-489.
Web of Science PubMed FullText FullText_MUG

 

2014

Hofstetter, B; Gamsjaeger, S; Varga, F; Dobnig, H; Stepan, JJ; Petto, H; Pavo, I; Klaushofer, K; Paschalis, EP Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
Osteoporos Int. 2014; 25(12):2709-2719
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Pavo, I; Haschka, J; Schima, W; Kapiotis, S; Resch, H Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
J Bone Miner Res. 2014; 29(8):1777-1785 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Roux, C; Hofbauer, LC; Ho, PR; Wark, JD; Zillikens, MC; Fahrleitner-Pammer, A; Hawkins, F; Micaelo, M; Minisola, S; Papaioannou, N; Stone, M; Ferreira, I; Siddhanti, S; Wagman, RB; Brown, JP Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Bone. 2014; 58(2):48-54 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Muschitz, C; Kocijan, R; Fahrleitner-Pammer, A; Lung, S; Resch, H Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
J Bone Miner Res. 2013; 28(1):196-205 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Bieglmayer, C; Dimai, HP; Gasser, RW; Kudlacek, S; Obermayer-Pietsch, B; Woloszczuk, W; Zwettler, E; Griesmacher, A Biomarkers of bone turnover in diagnosis and therapy of osteoporosis : A consensus advice from an Austrian working group.
Wien Med Wochenschr. 2012; 162(21-22):464-477
PubMed FullText FullText_MUG

 

Boonen, S; Reginster, JY; Kaufman, JM; Lippuner, K; Zanchetta, J; Langdahl, B; Rizzoli, R; Lipschitz, S; Dimai, HP; Witvrouw, R; Eriksen, E; Brixen, K; Russo, L; Claessens, F; Papanastasiou, P; Antunez, O; Su, GQ; Bucci-Rechtweg, C; Hruska, J; Incera, E; Vanderschueren, D; Orwoll, E; Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis.
N ENGL J MED. 2012; 367(18): 1714-1723. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Muschitz, C; Fahrleitner-Pammer, A; Huber, J; Preisinger, E; Kudlacek, S; Resch, H Update on denosumab in postmenopausal osteoporosis--recent clinical data.
Wien Med Wochenschr. 2012; 162(17-18):374-379
PubMed FullText FullText_MUG

 

Pirker-Frühauf, UM; Friesenbichler, J; Urban, EC; Obermayer-Pietsch, B; Leithner, A Osteoporosis in Children and Young Adults: A Late Effect After Chemotherapy for Bone Sarcoma.
Clin Orthop Relat Res. 2012; 470(10):2874-2885 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2011

Kuchler, U; Spilka, T; Baron, K; Tangl, S; Watzek, G; Gruber, R Intermittent parathyroid hormone fails to stimulate osseointegration in diabetic rats.
Clin Oral Implants Res. 2011; 22(5):518-523
Web of Science PubMed FullText FullText_MUG

 

2010

Herrmann, M; Seibel, MJ The effects of hormonal contraceptives on bone turnover markers and bone health.
Clin Endocrinol (Oxf). 2010; 72(5):571-583
Web of Science PubMed FullText FullText_MUG

 

Stepan, JJ; Burr, DB; Li, J; Ma, YL; Petto, H; Sipos, A; Dobnig, H; Fahrleitner-Pammer, A; Michalská, D; Pavo, I Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
Osteoporos Int. 2010; 21(12): 2027-2036.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2009

Cummings, SR; San Martin, J; McClung, MR; Siris, ES; Eastell, R; Reid, IR; Delmas, P; Zoog, HB; Austin, M; Wang, A; Kutilek, S; Adami, S; Zanchetta, J; Libanati, C; Siddhanti, S; Christiansen, C; FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
N Engl J Med. 2009; 361(8): 756-765. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Dimai, HP; Pietschmann, P; Resch, H; Preisinger, E; Fahrleitner-Pammer, A; Dobnig, H; Klaushofer, K; Austrian Society for Bone and Mineral Research (AuSBMR) Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009
Wien Med Wochenschr Suppl. 2009; (122): 1-34.
PubMed FullText FullText_MUG Google Scholar

 

Dobnig, H; Stepan, JJ; Burr, DB; Li, J; Michalská, D; Sipos, A; Petto, H; Fahrleitner-Pammer, A; Pavo, I Teriparatide Reduces Bone Microdamage Accumulation in Postmenopausal Women Previously Treated With Alendronate *
J Bone Miner Res. 2009; 24(12): 1998-2006. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Eastell, R; Black, DM; Boonen, S; Adami, S; Felsenberg, D; Lippuner, K; Cummings, SR; Delmas, PD; Palermo, L; Mesenbrink, P; Cauley, JA; HORIZON Pivotal Fracture Trial Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.
J Clin Endocrinol Metab. 2009; 94(9): 3215-3225. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Eastell, R; Nickelsen, T; Marin, F; Barker, C; Hadji, P; Farrerons, J; Audran, M; Boonen, S; Brixen, K; Gomes, JM; Obermayer-Pietsch, B; Avramidis, A; Sigurdsson, G; Glüer, CC Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
J Bone Miner Res. 2009; 24(4): 726-736. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Dubsky, P; Fitzal, F; Blaha, P; Schoppmann, S; Steger, G; Marth, C; Samonigg, H; Hüttner, K; Fohler, H; Ruecklinger, E; Jakesz, R; Greil, R; Austrian Breast and Colorectal Cancer Study Group Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Clin Breast Cancer. 2009; 9 Suppl 1: S18-S27.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2008

Boonen, S; Marin, F; Obermayer-Pietsch, B; Simões, ME; Barker, C; Glass, EV; Hadji, P; Lyritis, G; Oertel, H; Nickelsen, T; McCloskey, EV; for the EUROFORS Investigators Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
J Clin Endocrinol Metab. 2008; 93(3):852-860 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Kainberger, F; Kässmann, H; Piswanger-Sölkner, JC; Seifert, M; Ploner, F; Menzel, C; Dubsky, P; Fitzal, F; Bjelic-Radisic, V; Steger, G; Greil, R; Marth, C; Kubista, E; Samonigg, H; Wohlmuth, P; Mittlböck, M; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group (ABCSG) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Lancet Oncol. 2008; 9(9):840-849
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Minne, H; Audran, M; Simões, ME; Obermayer-Pietsch, B; Sigurðsson, G; Marín, F; Dalsky, GP; Nickelsen, T; EUROFORS Study Group Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study.
Curr Med Res Opin. 2008; 24(11):3117-3128 [Keynote lecture]
Web of Science PubMed FullText FullText_MUG

 

Obermayer-Pietsch, BM; Marin, F; McCloskey, EV; Hadji, P; Farrerons, J; Boonen, S; Audran, M; Barker, C; Anastasilakis, AD; Fraser, WD; Nickelsen, T Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment.
J BONE MINER RES. 2008; 23(10): 1591-1600. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Rajzbaum, G; Jakob, F; Karras, D; Ljunggren, O; Lems, WF; Langdahl, BL; Fahrleitner-Pammer, A; Walsh, JB; Gibson, A; Tynan, AJ; Marin, F Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
Curr Med Res Opin. 2008; 24(2): 377-384.
Web of Science PubMed FullText FullText_MUG

 

2007

Egner-Höbarth, S; Welkerling, H; Windhager, R Bisphosphonates in the therapy of fibrous dysplasia. Relevant data and practical aspects
Orthopade. 2007; 36(2): 126- 130.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Gnant, MF; Mlineritsch, B; Luschin-Ebengreuth, G; Grampp, S; Kaessmann, H; Schmid, M; Menzel, C; Piswanger-Soelkner, JC; Galid, A; Mittlboeck, M; Hausmaninger, H; Jakesz, R; Austrian Breast and Colorectal Cancer Study Group Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
J Clin Oncol. 2007; 25(7): 820-828. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Herrmann, M; Umanskaya, N; Traber, L; Schmidt-Gayk, H; Menke, W; Lanzer, G; Lenhart, M; Peter Schmidt, J; Herrmann, W The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients: a 1-year double blind placebo controlled trial.
Clin Chem Lab Med. 2007; 45(12):1785-1792
Web of Science PubMed FullText FullText_MUG

 

Stepan, JJ; Burr, DB; Pavo, I; Sipos, A; Michalska, D; Li, J; Fahrleitner-Pammer, A; Petto, H; Westmore, M; Michalsky, D; Sato, M; Dobnig, H Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
Bone. 2007; 41(3): 378-385.
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Dobnig, H; Hofbauer, LC; Viereck, V; Obermayer-Pietsch, B; Fahrleitner-Pammer, A Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Osteoporos Int. 2006; 17(5):693-703
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Asmus, HG; Braun, J; Krause, R; Brunkhorst, R; Holzer, H; Schulz, W; Neumayer, HH; Raggi, P; Bommer, J Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
Nephrol Dial Transplant. 2005; 20(8):1653-1661 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Dimai, HP Strontium ranelate: a novel concept for the treatment of osteoporosis
WIEN KLIN WOCHENSCHR. 2005; 117(21-22): 728-738.
Web of Science PubMed FullText FullText_MUG

 

2003

Fahrleitner, A; Prenner, G; Leb, G; Tscheliessnigg, KH; Piswanger-Sölkner, C; Obermayer-Pietsch, B; Portugaller, HR; Berghold, A; Dobnig, H Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation.
Bone. 2003; 32(1):96-106
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2002

Reid, IR; Brown, JP; Burckhardt, P; Horowitz, Z; Richardson, P; Trechsel, U; Widmer, A; Devogelaer, JP; Kaufman, JM; Jaeger, P; Body, JJ; Brandi, ML; Broell, J; Di Micco, R; Genazzani, AR; Felsenberg, D; Happ, J; Hooper, MJ; Ittner, J; Leb, G; Mallmin, H; Murray, T; Ortolani, S; Rubinacci, A; Saaf, M; Samsioe, G; Verbruggen, L; Meunier, PJ Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
N Engl J Med. 2002; 346(9):653-661 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2001

Neer, RM; Arnaud, CD; Zanchetta, JR; Prince, R; Gaich, GA; Reginster, JY; Hodsman, AB; Eriksen, EF; Ish-Shalom, S; Genant, HK; Wang, O; Mitlak, BH (Study group members, Leb, G; Dobnig, H; Fahrleitner, A) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
N ENGL J MED. 2001; 344(19): 1434-1441. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2000

Aringer, M; Vierhapper, H; Graninger, MT; Bernecker, P; Smolen, JS; Pietschmann, P Successful treatment of high turnover osteoporosis in a patient with adrenocortical insufficiency.
Wien Klin Wochenschr. 2000; 112(7):334-337 (- Case Report)
Web of Science PubMed

 

Orwoll, E; Ettinger, M; Weiss, S; Miller, P; Kendler, D; Graham, J; Adami, S; Weber, K; Lorenc, R; Pietschmann, P; Vandormael, K; Lombardi, A Alendronate for the treatment of osteoporosis in men.
N Engl J Med. 2000; 343(9):604-610 [OPEN ACCESS]
Web of Science PubMed FullText

 

1998

Masaryk, P; Lunt, M; Benevolenskaya, L; Cannata, J; Dequeker, J; Dohenhof, C; Falch, JA; Felsenberg, D; Pols, HA; Poor, G; Reid, DM; Scheidt-Nave, C; Weber, K; O'Neill, T; Silman, AJ; Reeve, J Effects of menstrual history and use of medications on bone mineral density: the EVOS Study.
Calcif Tissue Int. 1998; 63(4):271-276
Web of Science PubMed FullText FullText_MUG Google Scholar

 

1997

Erlacher, L; Kettenbach, J; Kiener, H; Graninger, W; Kainberger, F; Pietschmann, P Salmon calcitonin and calcium in the treatment of male osteoporosis: the effect on bone mineral density.
Wien Klin Wochenschr. 1997; 109(8): 270-274.
Web of Science PubMed Google Scholar

 

© Meduni Graz Impressum